Your shopping cart is currently empty

FR194738 free base inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $73 | - | In Stock | |
| 5 mg | $176 | - | In Stock | |
| 10 mg | $259 | - | In Stock | |
| 25 mg | $392 | - | In Stock | |
| 50 mg | $542 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $197 | - | In Stock |
| Description | FR194738 free base inhibits squalene epoxidase activity in HepG2 cell homogenates with an IC50 of 9.8 nM. |
| Targets&IC50 | SE (HepG2 cell homogenates):9.8 nM |
| In vitro | FR194738 free base potently inhibits squalene epoxidase in HepG2 cell homogenate and liver microsomes in dogs and rats. FR194738 free base inhibits hamster liver microsomal squalene epoxidase activity in a concentration-dependent manner with an IC50 of 14 nM[2]. In intact HepG2 cells, FR194738 free base inhibits the incorporation of [14C]acetate into free cholesterol and cholesteryl ester in a concentration-dependent manner(IC50s = 4.9 and 8.0 nM). FR194738 free base induces intracellular [14C]squalene accumulation and increases the incorporation of [14C]acetate into squalene[3]. |
| In vivo | FR194738 free base reduces the serum levels of total, non high density lipoprotein and high density lipoprotein cholesterol, and triglyceride. In hamsters, FR194738 free base(32 mg/kg) increases HMG-CoA reductase activity by 1.3-fold[2]. |
| Molecular Weight | 439.65 |
| Formula | C27H37NO2S |
| Cas No. | 204067-45-8 |
| Smiles | CCN(C\C=C\C#CC(C)(C)C)Cc1cccc(OCC(C)(C)OCc2ccsc2)c1 |
| Relative Density. | 1.051 g/cm3 (Predicted) |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (204.71 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.51 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.